5,604
Views
5
CrossRef citations to date
0
Altmetric
Editorial

What are the considerations for anti-hypertensive treatment in patients with Parkinson’s disease?

Pages 1127-1130 | Received 07 Jan 2020, Accepted 16 Mar 2020, Published online: 20 Mar 2020
 

Declaration of Interest

W Jost has served as an advisor and speakear for AbbVie, Allergan, Bial, Ipsen, UCB Pharma, Zambon, Desitin, and Merz. He has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer Disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This manuscript was not funded.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.